Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
LYXOR MSCI USA ESG LEADERS EXTRA (DR) UCITS ETF - ACC - USD	0.06%	330 M€	-.--%	-
ANFIELD U.S. EQUITY SECTOR ROTATION ETF - USD	0.06%	106 M€	+15.93%	-
LEVERAGE SHARES 3X LONG TOTAL WORLD ETP SECURITIES - USD	0.05%	0 M€	0.00%	-
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A (EUR) - EUR	0.05%	825 M€	+10.15%
OSSIAM BLOOMBERG USA PAB UCITS ETF - 1A - EUR HEDGED	0.05%	9 M€	+7.98%	-
REVERE SECTOR OPPORTUNITY ETF - USD	0.05%	6 M€	+17.98%	-
AGILITY SHARES MANAGED RISK ETF - USD	0.05%	133 M€	+8.99%	-
AMUNDI MSCI WORLD ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.04%	276 M€	+11.40%	-
CSIF (IE) MSCI USA BLUE UCITS ETF B ACC - USD	0.04%	2,567 M€	+14.65%	-
NEXT FUNDS S&P 500 (UNHEDGED) ETF - JPY	0.04%	61 M€	+23.05%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.03%	288 M€	+21.58%
HSBC MSCI USA UCITS ETF - USD	0.03%	35 M€	+13.39%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DAILY HEDGED TO EUR - ACC - HEDGED EUR	0.03%	273 M€	-.--%
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.03%	655 M€	-.--%	-
LYXOR NET ZERO 2050 S&P 500 CLIMATE PAB (DR) UCITS ETF - DIST - USD	0.03%	1,174 M€	+23.54%
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.02%	205 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	414 M€	+10.01%	-
NIGHTSHARES 500 1X/1.5X ETF - USD	0.02%	14 M€	+16.19%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR ETF - USD	0.02%	560 M€	+8.56%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.02%	206 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	36 M€	+9.83%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.02%	284 M€	-.--%
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.02%	607 M€	+0.05%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.02%	1,166 M€	+0.26%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - USD	0.02%	23 M€	-.--%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB UCITS ETF DR (C) - EUR	0.02%	786 M€	-.--%

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-06-10 - Goldman Sachs Global Healthcare Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

59.16 USD

Average target price

72.8 USD

Spread / Average Target

+23.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-5.78%	13.3B
CSL LIMITED	+0.82%	91.94B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.74B
BIOGEN INC.	-12.88%	32.82B
UCB	+64.77%	26.66B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.32B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B
ALTEOGEN INC.	+173.10%	10.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	9.06B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
59.16 ^USD	+1.28%		+2.37%	-5.78%

May. 23	Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	MT
May. 21	Incyte Acquires 2 Office Buildings in Delaware	MT